Comparative Pharmacology
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMIFLOXACIN MESYLATE versus MOXAM.
GEMIFLOXACIN MESYLATE vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
320 mg orally once daily for 7-14 days
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic